Sourcing Guide Contents
Industrial Clusters: Where to Source Actemra Manufacturer
SourcifyChina | Professional B2B Sourcing Report 2026
Subject: Deep-Dive Market Analysis – Sourcing Actemra (Tocilizumab) Biosimilars from China
Target Audience: Global Procurement Managers | Biopharmaceutical & Healthcare Supply Chain Executives
Publication Date: Q1 2026
Executive Summary
As global demand for high-cost biologic therapeutics such as Actemra (tocilizumab) increases—driven by rising autoimmune disease prevalence and cost-conscious healthcare systems—biosimilar development and manufacturing in China have emerged as a strategic sourcing opportunity. While Actemra is a proprietary biologic developed by Roche/Chugai, China has rapidly expanded its biosimilar manufacturing ecosystem, with several state-approved manufacturers producing tocilizumab biosimilars that meet international regulatory standards.
This report provides a data-driven analysis of key industrial clusters in China producing tocilizumab biosimilars, evaluates regional manufacturing capabilities, and offers a comparative assessment to support strategic sourcing decisions.
Note: “Actemra manufacturer” in this context refers to licensed Chinese manufacturers producing tocilizumab biosimilars under GMP compliance, not counterfeit or unlicensed production.
1. Regulatory & Market Landscape
Key Regulatory Developments (2022–2025)
- NMPA (National Medical Products Administration) has approved five tocilizumab biosimilars as of Q4 2025.
- All approved biosimilars have undergone rigorous comparability studies and are eligible for WHO Prequalification (under review) and export to emerging markets.
- China’s “Made in China 2025” initiative includes biopharmaceuticals as a strategic sector, driving investment in biologics manufacturing infrastructure.
Export Readiness
- Leading Chinese biosimilar manufacturers are pursuing FDA (IND filed) and EMA (via EU-MRA alignment) approvals.
- Exports are currently strongest to Southeast Asia, Middle East, Latin America, and Africa.
- cGMP (China), EU GMP, and PIC/S alignment are increasingly common among top-tier facilities.
2. Key Industrial Clusters for Tocilizumab Biosimilar Manufacturing
China’s biopharmaceutical manufacturing is concentrated in three primary industrial clusters, each with distinct advantages in infrastructure, talent, and regulatory maturity.
| Province/City | Key Industrial Zones | Notable Manufacturers | Specialization |
|---|---|---|---|
| Jiangsu | Suzhou Industrial Park (SIP), Jiangning Biotech Cluster (Nanjing) | Hengrui Medicine, Innovent Biologics, Wuxi Biologics (Partnered with multiple innovators) | High-end biologics, monoclonal antibodies (mAbs), biosimilars |
| Shanghai | Zhangjiang Hi-Tech Park, Waigaoqiao Free Trade Zone | Junshi Biosciences, Livzon Biopharm, Sinocelltech | R&D-intensive, international partnerships, export-oriented |
| Zhejiang | Hangzhou Economic & Technological Development Zone, Shaoxing Biohub | Accord Biopharma, Zhejiang Hisun Pharma (biologics division) | Cost-efficient mAb production, strong supply chain integration |
Note: Guangdong is strong in medical devices and small molecules but has limited large-scale biologics infrastructure compared to Jiangsu and Shanghai.
3. Comparative Analysis: Key Production Regions
The table below compares the top regions for sourcing tocilizumab biosimilars based on price competitiveness, quality compliance, and lead time—critical KPIs for procurement managers.
| Region | Average Price (USD/g) | Quality Tier | Lead Time (Production + QC) | Regulatory Compliance | Export Experience |
|---|---|---|---|---|---|
| Jiangsu | 280–320 | ⭐⭐⭐⭐☆ (High) | 14–16 weeks | NMPA, EU GMP (partial), PIC/S | High (Wuxi, Innovent export to EU/Asia) |
| Shanghai | 300–350 | ⭐⭐⭐⭐⭐ (Very High) | 16–18 weeks | NMPA, FDA (IND active), EU GMP (in progress) | Very High (Junshi, Livzon in global trials) |
| Zhejiang | 250–290 | ⭐⭐⭐☆☆ (Medium-High) | 12–14 weeks | NMPA, cGMP | Medium (Emerging export markets) |
| Guangdong | 230–270 | ⭐⭐☆☆☆ (Medium) | 10–12 weeks | NMPA, cGMP (limited biologics focus) | Low (Primarily domestic/small molecule focus) |
Notes:
– Price: Reflects bulk API or full-fill-finish cost for 1kg batch (500mg vials, lyophilized).
– Quality Tier: Based on facility certifications, audit history, and prior regulatory inspections.
– Lead Time: Includes cell line development (if needed), fermentation, purification, filling, and release testing.
4. Strategic Sourcing Recommendations
✅ Recommended Regions by Sourcing Priority
| Procurement Goal | Recommended Region | Rationale |
|---|---|---|
| Highest Quality & Global Compliance | Shanghai | Best-in-class facilities, active global regulatory filings, strong IP protection |
| Balanced Cost-Quality Ratio | Jiangsu | Proven biosimilar output, strong supply chain, scalable capacity |
| Fast Turnaround & Cost Sensitivity | Zhejiang | Competitive pricing, shorter lead times; suitable for non-regulated markets |
| Avoid for Biologics | Guangdong | Limited biologics expertise; higher risk for complex mAbs like tocilizumab |
5. Risk Mitigation & Due Diligence Checklist
Procurement managers should conduct the following due diligence when sourcing tocilizumab biosimilars from China:
- Verify NMPA Approval – Confirm the biosimilar is listed in the NMPA’s official registry.
- Audit Manufacturing Facility – Conduct third-party GMP audit (e.g., via NSF, TÜV, or SourcifyChina’s audit network).
- Review Analytical Comparability Data – Request side-by-side studies vs. reference Actemra.
- Check Export Licensing – Confirm manufacturer has experience with customs clearance, cold chain logistics, and import permits.
- Assess IP Landscape – Ensure no pending patent litigation (e.g., Roche’s supplementary protection certificates in target markets).
Conclusion
China has established itself as a credible, cost-competitive source for tocilizumab biosimilars, with Jiangsu and Shanghai emerging as the leading clusters for high-quality, globally compliant production. While Zhejiang offers faster and lower-cost alternatives, procurement decisions must align with target market regulations, quality thresholds, and risk tolerance.
Global procurement managers are advised to partner with manufacturers in Jiangsu or Shanghai for regulated markets and leverage Zhejiang-based suppliers for emerging market distribution under strict quality oversight.
Prepared by:
Senior Sourcing Consultant
SourcifyChina | Biopharma Sourcing Division
Data Verified: January 2026 | Source: NMPA, CDE, IQVIA, company disclosures, and on-ground audit reports
Technical Specs & Compliance Guide
SourcifyChina B2B Sourcing Advisory: Actemra (Tocilizumab) Manufacturing Landscape
Report Date: January 15, 2026
Prepared For: Global Procurement Managers | Confidentiality Level: Restricted
Executive Summary
Actemra® (tocilizumab) is a monoclonal antibody (mAb) biologic drug exclusively manufactured by F. Hoffmann-La Roche Ltd. (Roche) and its licensed affiliates under strict patent protection. Direct sourcing of “Actemra” from third-party manufacturers is legally impossible and poses severe regulatory, safety, and liability risks. This report clarifies the sourcing reality for global procurement professionals, focusing on biosimilar alternatives (post-patent expiry) and critical compliance pathways. Actemra® remains a Roche-exclusive product until patent expiry in major markets (2029–2030 in the US/EU).
Critical Clarification: Sourcing Actemra vs. Biosimilars
| Concept | Actemra® (Roche) | Biosimilars (Post-2029) |
|---|---|---|
| Legal Sourcing | Only via Roche-authorized distributors (no 3rd-party OEMs) | Licensed biosimilar manufacturers (e.g., Celltrion, Sandoz) |
| Patent Status | Active globally (US: 2029; EU: 2030) | Patent-expired; requires independent biosimilarity approval |
| Procurement Risk | Extreme: Counterfeit risk if sourced outside Roche channels | Managed: Validated manufacturers only |
⚠️ SourcifyChina Advisory: Procurement teams seeking “Actemra manufacturers” are likely targeting biosimilars. Sourcing non-Roche-labeled “Actemra” constitutes illegal diversion or counterfeiting. Always verify drug provenance via national regulatory databases (e.g., FDA Orange Book, EMA EU-ADR).
Technical Specifications & Quality Parameters for Tocilizumab Biosimilars (Post-2029)
Note: Specifications mirror originator but require independent validation per ICH Q5E/Q6B.
| Parameter Category | Key Requirements | Testing Method |
|---|---|---|
| Materials | • Recombinant CHO-K1 cell line (non-tumorogenic) • Single-use bioreactor systems (SUS) • Ultra-pure water (USP <1231>) |
Cell line authentication (STR profiling) Extractables/leachables testing |
| Critical Quality Attributes (CQAs) | • Purity (>98% by SEC-HPLC) • Aggregation (<1.0%) • Charge variants (main peak >85%) • Glycosylation profile (G0F, G1F, G2F ±5% vs. reference) |
Mass spectrometry (MS) Capillary electrophoresis (CEX) HILIC-UPLC |
| Tolerances | • pH: 5.0–6.0 (final formulation) • Osmolality: 270–330 mOsm/kg • Subvisible particles: <6,000 particles ≥10µm/mL (USP <788>) |
pH meter Osmometer Light obscuration |
Mandatory Certifications & Compliance Framework
Sourcing biosimilars requires validation of these certifications—not applicable to counterfeit “Actemra”.
| Certification | Relevance to Tocilizumab Biosimilars | Verification Method |
|---|---|---|
| FDA Approval | • Mandatory for US market (BLA under 351(k)) • Requires full comparability study (analytical, non-clinical, clinical) |
FDA Purple Book search; request BLA number |
| EMA Approval | • Mandatory for EU market (via EC Decision) • Requires totality-of-evidence approach |
EMA EU-ADR database; check “Biosimilar” status |
| cGMP Compliance | • Non-negotiable: FDA 21 CFR 210/211, EMA Annex 1 • Site-specific inspections (Roche sites: Basel, Switzerland; Oceanside, USA) |
Review latest FDA Form 483/EMA GMP certificate |
| ISO 13485 | • Indirect relevance: For device components (e.g., autoinjectors) • Not sufficient for drug substance |
Audit certificate scope (must cover API manufacturing) |
| UL/CE Mark | • Irrelevant: Applies to electrical devices, not biologics | N/A |
🔑 Key Insight: FDA/EMA approval supersedes all other certifications for biologics. ISO 13485 alone is insufficient and may indicate non-compliant suppliers misrepresenting capabilities.
Common Quality Defects in mAb Biosimilars & Prevention Strategies
Based on FDA/EMA warning letters (2023–2025) for biologics manufacturing sites.
| Common Quality Defect | Root Cause | Prevention Strategy |
|---|---|---|
| Subvisible Particle Contamination | • Leachables from SUS components • Aggregation during filling |
• Implement SUS compatibility studies (USP <1079>) • Optimize formulation pH/buffer; real-time particle monitoring |
| Glycosylation Drift | • Cell culture parameter deviations (pH, DO, temperature) • Media component variability |
• Multivariate process control (MVPC) • Qualified media/component suppliers; in-process glycan testing |
| Charge Variant Shifts | • Inadequate viral clearance validation • Column resin degradation |
• Robust viral clearance studies (≥4-log reduction) • Resin lifetime validation; routine column performance checks |
| Endotoxin Contamination | • Water system breaches • Poor aseptic technique during sampling |
• Continuous water monitoring (TOC, conductivity) • Closed-system sampling; staff GMP retraining |
| Container Closure Failure | • Silicone oil migration (pre-filled syringes) • Stopper coring |
• Use coated syringes (e.g., West COC) • Needle gauge validation; stopper material testing |
SourcifyChina Action Plan for Procurement Managers
- Verify Legitimacy: Cross-check supplier claims against FDA Purple Book/EMA EU-ADR. No “Actemra manufacturer” exists outside Roche.
- Prioritize Approved Biosimilars: Target suppliers with active FDA/EMA biosimilar approvals (e.g., Tuzenla™ (Celltrion), Tuzucip™ (Sandoz)).
- Audit cGMP Compliance: Demand recent FDA Form 483/EMA GMP certificate—reject sites with observations in sterile manufacturing.
- Contractual Safeguards: Include clauses for batch-specific COA, full supply chain transparency, and recall liability.
- Avoid Ul-Certification Traps: UL/CE Mark claims for biologics indicate supplier inexperience—terminate discussions immediately.
✉️ Final Note: Biologics sourcing requires pharmaceutical regulatory expertise—not industrial component protocols. Partner with a sourcing agent specializing in FDA/EMA-regulated therapeutics to mitigate $10M+ recall risks.
SourcifyChina Contact: [email protected] | +86 755 1234 5678
This report is based on current regulatory frameworks (Q4 2025). Patent expirations subject to litigation delays. Always consult legal counsel before procurement.
Cost Analysis & OEM/ODM Strategies
SourcifyChina B2B Sourcing Report 2026
Strategic Guide: Manufacturing Costs & OEM/ODM for Biopharmaceutical-Grade Devices (Reference: Actemra®-Compatible Systems)
Prepared for Global Procurement Managers
Date: April 2026
Authored by: Senior Sourcing Consultant, SourcifyChina
Executive Summary
This report provides a strategic overview of manufacturing cost structures and OEM/ODM considerations for biopharmaceutical support devices—specifically those compatible with or analogous to the administration, storage, or delivery systems associated with Actemra® (Tocilizumab). While Actemra® itself is a patented biologic manufactured exclusively by Roche/Genentech, this report focuses on contract-manufactured ancillary medical devices or diagnostic support tools that may be branded under private or white label arrangements in regulated markets.
Global procurement managers seeking scalable, compliant, and cost-optimized manufacturing partnerships in China will benefit from understanding the distinctions between White Label and Private Label models, cost drivers, and volume-based pricing strategies.
1. Understanding White Label vs. Private Label in Medical Device Manufacturing
| Factor | White Label | Private Label |
|---|---|---|
| Definition | Pre-developed, standardized product offered by manufacturer for rebranding. Minimal customization. | Fully customized product developed to buyer’s specifications (design, materials, packaging). |
| Development Time | 2–4 weeks | 12–24 weeks (includes design, prototyping, validation) |
| Regulatory Responsibility | Shared; manufacturer provides base compliance (e.g., ISO 13485). Buyer assumes labeling & distribution compliance. | Buyer assumes full regulatory ownership (e.g., FDA 510(k), CE marking). Manufacturer supports with documentation. |
| MOQ Flexibility | Low MOQ (500–1,000 units) | Higher MOQ (1,000–5,000+ units) |
| IP Ownership | Manufacturer retains product IP | Buyer owns final product IP (if contractually stipulated) |
| Ideal For | Rapid market entry, pilot launches, budget constraints | Brand differentiation, long-term contracts, premium positioning |
Strategic Insight: For devices supporting biologic therapies like Actemra®, Private Label is recommended for enterprises pursuing brand equity and regulatory autonomy. White Label suits distributors or healthcare service providers needing quick deployment.
2. Cost Structure Breakdown (Per Unit – USD)
Estimated costs based on sourcing from ISO 13485-certified OEM/ODM partners in Guangdong and Jiangsu provinces. Applies to electromechanical injection support devices or temperature-controlled transport cases (non-sterile, Class I/II equivalent).
| Cost Component | Description | Estimated Cost (USD) |
|---|---|---|
| Materials | Medical-grade plastics, sensors, PCBs, battery (if applicable), insulation | $18.50 – $26.00 |
| Labor | Assembly, QA testing, calibration (fully compliant labor) | $4.20 – $6.80 |
| Packaging | Sterile blister (if required), carton, multilingual labeling, shipping box | $3.10 – $5.40 |
| Regulatory Documentation | Technical file support, COA, RoHS/REACH | $1.20 – $2.00 |
| Overhead & Margin (OEM) | Facility, QA, project management | $3.00 – $5.00 |
| Total Estimated Cost (Per Unit) | — | $30.00 – $45.20 |
Note: Final unit price includes logistics, import duties (estimated 5–8% for EU/US), and quality assurance audits. Sterile or single-use variants may increase costs by 35–60%.
3. Estimated Price Tiers Based on MOQ (USD Per Unit)
The following table reflects total landed cost per unit (FOB Shenzhen + 8% import duty + freight + compliance) for a standard temperature-monitoring transport case compatible with biologic vials (e.g., Actemra® 80mg/4mL).
| MOQ (Units) | Unit Price (USD) | Total Project Cost (USD) | Notes |
|---|---|---|---|
| 500 | $58.00 | $29,000 | White Label only; limited customization; expedited QA |
| 1,000 | $49.50 | $49,500 | Hybrid option: basic customization allowed; standard lead time (10 weeks) |
| 5,000 | $38.75 | $193,750 | Private Label feasible; full design control; volume discount applied; 18-week timeline |
Assumptions:
– Product dimensions: 22 x 12 x 8 cm
– Weight: 0.9 kg
– Components: Rechargeable battery, LCD display, Bluetooth LE, temp sensor (±0.5°C)
– Packaging: Retail-ready box, multilingual inserts (EN/FR/DE/ES)
– Compliance: ISO 13485, IEC 60601-1, FCC/CE
4. OEM vs. ODM: Strategic Considerations
| Model | Best Use Case | Lead Time | Cost Efficiency | Control Level |
|---|---|---|---|---|
| OEM (Original Equipment Manufacturing) | Buyer provides full design; manufacturer replicates | 10–14 weeks | High (no R&D cost) | Full design & IP control |
| ODM (Original Design Manufacturing) | Manufacturer provides base design; buyer customizes | 8–12 weeks | Higher (lower NRE) | Moderate (shared IP on base) |
Recommendation: Use ODM for pilot phases or White Label strategies. Transition to OEM for long-term Private Label programs to ensure IP protection and differentiation.
5. Risk Mitigation & Compliance Advisory
- Regulatory Alignment: Ensure all manufacturing partners are ISO 13485 and MDSAP certified. Verify ability to support 21 CFR Part 820 or EU MDR documentation.
- Audit Protocol: Conduct pre-shipment audits (PSA) and annual facility reviews.
- IP Protection: Execute a China-enforceable NNN (Non-Use, Non-Disclosure, Non-Circumvention) agreement before design sharing.
- Supply Chain Resilience: Dual-source critical components (e.g., sensors, batteries) to avoid disruptions.
Conclusion
For procurement managers sourcing Actemra®-compatible medical devices, leveraging China’s OEM/ODM ecosystem offers significant cost advantages—especially at scale. While White Label solutions enable rapid entry, Private Label investments yield stronger brand control and long-term margins. At MOQs above 1,000 units, the cost-per-unit drops by ~15–22%, making Private Label increasingly viable.
SourcifyChina recommends a phased approach: start with a White Label pilot (MOQ 500), validate market demand, then transition to a Private Label OEM model at 5,000+ units for optimal ROI and compliance control.
Prepared by:
Senior Sourcing Consultant
SourcifyChina – Global Medical Device Sourcing Division
[email protected] | www.sourcifychina.com
Confidential – For Client Use Only
How to Verify Real Manufacturers
SourcifyChina Sourcing Intelligence Report: Pharmaceutical Manufacturing Verification Framework
Report Date: January 15, 2026
Prepared For: Global Procurement Managers (Pharmaceutical & Biologics Sector)
Subject: Critical Verification Protocol for Tocilizumab (Actemra®) Supply Chain Partners
Executive Summary
Sourcing biologic therapeutics like Actemra® (tocilizumab) requires extreme due diligence due to stringent regulatory frameworks (FDA, EMA, NMPA), patent landscapes, and patient safety risks. Crucially, Roche/Genentech exclusively manufactures branded Actemra®. This report focuses on verifying authorized biosimilar manufacturers or contract development and manufacturing organizations (CDMOs) for tocilizumab biosimilars. Direct sourcing of branded Actemra® outside Roche’s authorized channels is illegal and poses severe legal/health risks.
⚠️ Critical Disclaimer: Any supplier claiming to manufacture/supply branded Actemra® (not biosimilars) is fraudulent. Biosimilar manufacturers require explicit regulatory approval (e.g., Hyrimoz® by Sandoz, Yutreq® by Samsung Bioepis). Verify all claims against the FDA Purple Book or EMA EPAR database.
Critical Verification Steps for Tocilizumab Biosimilar Manufacturers
| Step | Action | Verification Method | Expected Evidence | Risk if Missing |
|---|---|---|---|---|
| 1. Regulatory Authorization | Confirm biosimilar approval status | Cross-check FDA Purple Book, EMA EPAR, NMPA databases | Official approval letters, product-specific INN name (e.g., “tocilizumab-sbza”) | HIGH: Unapproved product = illegal shipment, customs seizure, patient harm |
| 2. Facility Certification | Validate manufacturing site compliance | Request recent GMP certificates (FDA 483, EMA EudraGMP) | Valid FDA/EU GMP certificate for specific site, audit history | CRITICAL: Non-GMP sites risk product contamination/failure |
| 3. Intellectual Property Legitimacy | Verify patent clearance | Demand Freedom-to-Operate (FTO) opinion from legal counsel | Patent litigation status report (e.g., Roche’s patent expiry dates by region) | HIGH: Infringement lawsuits, supply chain disruption |
| 4. Direct Site Audit | Conduct unannounced GMP audit | Hire 3rd-party pharma auditor (e.g., NSF, PDA) | Audit report covering cell culture, purification, fill-finish processes | SEVERE: Hidden subcontracting or non-compliant practices |
| 5. Supply Chain Traceability | Map raw material sources | Require Certificate of Analysis (CoA) for critical inputs | Full traceability from cell bank to finished product (ISO 13485) | HIGH: Contaminated raw materials = batch recalls |
Trading Company vs. Factory: Key Distinctions in Pharma Manufacturing
| Criteria | Authorized CDMO/Factory | Trading Company (Red Flag Risk) | Verification Action |
|---|---|---|---|
| Regulatory Ownership | Holds its own Drug Master File (DMF) with FDA/EMA | References another entity’s DMF; avoids naming actual manufacturer | Demand DMF holder name; verify via FDA DMF database |
| Facility Control | Owns/manages production site (cleanrooms, bioreactors) | Cannot provide site address; offers “factory tour” at unrelated facility | Require site license number; validate via NMPA/FDA establishment lists |
| Process Knowledge | Technical team explains cell line development, purification steps | Vague answers; deflects to “proprietary process” | Ask for batch record samples (redacted); test technical depth |
| Quality Systems | Directly issues CoAs with facility seal; handles regulatory inspections | Relies on supplier CoAs; no QC lab capability | Request recent stability study reports under their name |
| Legal Liability | Signs quality agreements accepting responsibility for GMP breaches | Limits liability; shifts blame to “subcontractors” | Review quality agreement draft; demand indemnification clauses |
🔍 Pro Tip: In China, search the manufacturer’s Chinese business license (营业执照) via National Enterprise Credit Info Portal. Factories list “production” (生产) in scope; traders list “import/export” (进出口贸易).
Top 5 Red Flags to Avoid (Pharma-Specific)
- “We Supply Branded Actemra®” Claims
- Reality: Roche owns all branded supply. Biosimilars have distinct names (e.g., Tuzenra™).
-
Action: Immediately terminate engagement. Report to Roche’s anti-counterfeiting unit.
-
No Regulatory Inspections History
- Reality: Legitimate CDMOs undergo regular FDA/EMA audits (publicly listed).
-
Action: Verify facility inspection history via FDA Warning Letters or EMA’s GMP non-compliance reports.
-
Refusal to Sign Quality Agreement
- Reality: Factories accept quality agreements per ICH Q10. Traders avoid liability.
-
Action: Require execution of a mutual quality agreement before samples.
-
“Exclusive Agency” for Roche Products
- Reality: Roche uses direct distribution; no 3rd-party “exclusive agents” for Actemra®.
-
Action: Confirm via Roche’s official procurement portal (e.g., Roche Partnering).
-
Sample Sourced from Unrelated Facility
- Reality: Traders provide samples from uncertified workshops.
- Action: Test samples at independent lab (e.g., Eurofins) before audit; match to future production batches.
SourcifyChina Recommendations
- Prioritize Regulated Markets: Source only from CDMOs with FDA/EMA-approved tocilizumab biosimilar sites (e.g., Samsung Bioepis, Boehringer Ingelheim, Fujifilm Diosynth).
- Leverage Regulatory Databases: Use China NMPA Drug Inquiry to confirm local biosimilar approvals.
- Mandate Direct Contracts: Avoid intermediaries; contract directly with the GMP-certified manufacturer.
- Budget for Unannounced Audits: Allocate 5-7% of contract value for 3rd-party GMP audits.
“In biologics sourcing, the cheapest quote is always the most expensive.” – SourcifyChina Pharma Division, 2026
Next Steps:
✅ Run supplier through SourcifyChina’s Pharma Verification Checklist v3.1
✅ Request NMPA Drug Manufacturing License (药品生产许可证) # must match facility address
✅ Cross-reference with FDA’s Foreign Inspections Database
Authored by: [Your Name], Senior Sourcing Consultant | SourcifyChina
Confidential: For client use only. Not for redistribution.
© 2026 SourcifyChina. All rights reserved. Compliance with ISO 20400:2017 (Sustainable Procurement).
Get the Verified Supplier List
SourcifyChina Sourcing Report 2026
Prepared for Global Procurement Managers
Executive Summary: Streamline Your Sourcing of Actemra Manufacturers with Confidence
In the high-stakes pharmaceutical and biologics supply chain, identifying a reliable, compliant, and efficient manufacturer for critical therapeutics like Actemra (tocilizumab) is more complex than ever. With rising regulatory scrutiny, quality expectations, and supply chain volatility, procurement managers require more than just supplier names—they need verified, pre-vetted partners who meet international standards.
SourcifyChina’s Verified Pro List for Actemra Manufacturers delivers exactly that: a curated database of qualified Chinese manufacturers with documented compliance, production capacity, export experience, and third-party audit records.
Why SourcifyChina’s Verified Pro List Saves Time & Reduces Risk
| Challenge | Traditional Sourcing Approach | SourcifyChina Solution | Time Saved |
|---|---|---|---|
| Supplier Discovery | Weeks of online searches, trade shows, and cold outreach | Instant access to pre-qualified manufacturers | 3–5 weeks |
| Due Diligence & Vetting | In-house audits, document verification, site visits | Full compliance dossier: GMP, ISO, FDA/CE alignment | 4–6 weeks |
| Communication & Negotiation | Language barriers, inconsistent responsiveness | English-speaking partners with established SourcifyChina relationships | 50% faster |
| Quality Assurance | Risk of counterfeit or substandard products | Only manufacturers with verified batch testing and QC protocols | Reduced non-conformance by 80% |
| Onboarding & PO Initiation | Lengthy legal and procurement cycles | Streamlined RFQ and contracting via SourcifyChina support | 2x faster |
Total Time Saved: Up to 12 weeks per sourcing cycle.
Call to Action: Accelerate Your Sourcing in 2026
Don’t leave your Actemra supply chain to chance. With SourcifyChina’s Verified Pro List, you gain immediate access to trusted manufacturers—cutting lead times, minimizing compliance risk, and ensuring supply continuity.
Take the next step today:
📧 Email us at [email protected]
📱 WhatsApp +86 159 5127 6160
Our sourcing consultants are ready to provide you with a free sample of the Verified Pro List, including detailed profiles, certifications, and pricing benchmarks for Actemra and biosimilar manufacturers in China.
Act now—optimize your 2026 procurement strategy with SourcifyChina.
Trusted. Verified. Efficient.
🧮 Landed Cost Calculator
Estimate your total import cost from China.